GRFS News & Events

Grifols says Q1 results support FY26 guidance

Reports Q1 total revenue EUR 1.7B, up 3.3% y/y cc. Group profit increased to EUR 73M in the first quarter, up 21.9% year-on-year. Nacho Abia, CEO of Grifols, said: "We started the year delivering performance in line with our expectations and reassured that we are on track to achieve our guidance for the full-year 2026 as we continue to build momentum over the course of the year. These results were achieved in a complex geopolitical and macroeconomic environment, marked by persistent uncertainties. In this context, these results underscore both the resilience of our business and the strength of our underlying fundamentals."

Health Canada has imposed new terms and conditions on all of Grifols' paid plasma centers following multiple failed inspections that identified recurring systemic deficiencies, including inadequate donor screening, poor investigation of errors, insufficient staff training, and failure to follow operating procedures, Kristin Annable and Michelle Allan of CBC News reports. The action follows two donor deaths in Winnipeg and deficiencies found during an inspection of the company's Canadian head office, which oversees all 16 collection sites. A spokesperson for Health Canada says the conditions will remain in place until Grifols shows "sustained compliance" with blood regulations at all licensed sites.